Drug intelligence / Profile preview

KS101 + KS104

Development stage: Preclinical
Lead developer: Klotho Sciences
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

KS101 + KS104 is a combination of two small-molecule modulators targeting the Klotho protein, currently under development by Klotho Sciences. The Klotho protein is a pleiotropic protein primarily expressed in the kidneys and brain, functioning as a coreceptor for fibroblast growth factor 23 (FGF23) and acting as a circulating hormone with anti-aging, anti-oxidative, and anti-inflammatory properties. This specific combination therapy is being advanced for the treatment of osteoarthritis and conditions associated with old age. By modulating Klotho activity, the drug aims to mitigate the pathological processes associated with aging and joint degradation. It is currently in the IND-enabling stage of development.

Targets

KL (Klotho Protein)

Beyond the preview

Go deeper on KS101 + KS104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS101 + KS104.

Explore the full profile